Is there a Mounjaro pill? The straight answer

Is there a Mounjaro pill or tablet?

No. Mounjaro and Zepbound both contain tirzepatide from Eli Lilly, and both US labels describe a single form: an injection under the skin, once a week, into the abdomen or thigh, or the back of the upper arm if someone else gives it.^1,2 It comes as a single-dose pen, a single-dose vial, a four-dose vial or a four-dose KwikPen, in six strengths from 2.5 mg to 15 mg.^1,2

Eli Lilly does make a GLP-1 pill, Foundayo, but it contains a different medicine, orforglipron, with its own trials and its own label.³ Any GLP-1 pill is a different medicine from Mounjaro, so the choice between them is a prescribing decision, made with your prescriber.

The GLP-1 pills approved in the US, next to Mounjaro

From each medicine's US label. Forms are manufacturing facts, not a dose to take. For every GLP-1 medicine in one list, see GLP-1 medications compared.

Each medicine was tested in its own trials, so results can't be compared across rows. None of the tablets contains tirzepatide.^3,5,7

Foundayo: Lilly's GLP-1 pill, not a Mounjaro tablet

Foundayo (orforglipron) is Eli Lilly's once-daily GLP-1 tablet. The FDA approved it on April 1, 2026, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or with overweight and at least one weight-related condition.^3,4 Orforglipron was discovered by Chugai Pharmaceutical and licensed by Lilly in 2018.⁴

It differs from tirzepatide on almost every line of the label. Orforglipron is a small molecule rather than a peptide, and its label describes a GLP-1 receptor agonist, while tirzepatide activates both GIP and GLP-1 receptors.^1,3,4 Foundayo is swallowed once a day, with or without food and with no fasting or water rules in its label; Mounjaro and Zepbound are injected once a week.^1,3 Orforglipron's half-life is about 29 to 49 hours, against about 5 days for tirzepatide.^1,3

Foundayo comes in six strengths, from 0.8 mg to 17.2 mg, and its label, like Mounjaro's, starts low and steps up gradually; your prescriber sets the steps.^1,3 Because the two are different molecules, their milligrams can't be compared or converted. Even two semaglutide tablets, Rybelsus and Ozempic tablets, are "not substitutable on a mg-to-mg basis", according to their label.⁷

The Zepbound and Foundayo labels both say using them with another GLP-1 medicine is not recommended, and neither sets out a schedule for moving between them.^2,3 If a daily tablet interests you, that is a conversation for your prescriber. Foundayo vs Zepbound sets out the label facts side by side, and our Foundayo tracker covers day-to-day use.

How does Foundayo compare with Mounjaro or Zepbound?

No trial has compared them directly. In separate 72-week trials in adults without diabetes, average weight change was −11.1% on Foundayo 17.2 mg (placebo −2.1%) and −20.9% on Zepbound 15 mg (placebo −3.1%), both counting everyone who was randomly assigned.^2,3 Separate trials enroll different people, so these figures can't say how the two would compare for any one person, and they are averages, not predictions.

The other GLP-1 pills: semaglutide tablets

The rest of the GLP-1 pills contain semaglutide, the medicine in Ozempic and Wegovy injections, made by Novo Nordisk. None contains tirzepatide.

The Wegovy pill comes in 1.5, 4, 9 and 25 mg tablets and was approved on December 22, 2025, for weight management and for lowering the risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight.^5,6 It is taken once a day on an empty stomach in the morning, with up to 4 ounces of plain water, then at least 30 minutes before food, drink or other medicines by mouth.⁵

Ozempic tablets (1.5, 4 and 9 mg) and Rybelsus (3, 7 and 14 mg) are oral semaglutide for adults with type 2 diabetes, with the same morning routine.⁷ In the US, the newer tablets were renamed Ozempic tablets in the label on January 30, 2026, and Novo Nordisk said they would be available from May 4, 2026; it says Rybelsus will continue to be marketed outside the US.^7,8

To see the pills' label facts side by side, read Foundayo vs Wegovy and Wegovy pill vs injection.

Mounjaro tablets in the UK

There are no Mounjaro tablets in the UK either. Mounjaro is licensed there for type 2 diabetes and weight management, and it is given by injection, including a four-dose KwikPen that the MHRA approved in January 2024.⁹

The UK's GLP-1 tablets for weight loss are newer. The MHRA approved the Wegovy tablet on June 11, 2026, calling it the UK's first GLP-1 tablet for weight loss, and authorized Foundayo on August 10, 2026, for weight management and type 2 diabetes. It says neither is currently available on the NHS.^10,11

UK product information can be worded differently from US labels, so the leaflet in your pack is the one to follow. Handle records a Mounjaro KwikPen, or a tablet under "Something else", in the same way.

Questions to bring to your prescriber

Whether a pill or an injection suits you depends on your health, your other medicines, your routine and your coverage. These questions help that conversation.

1. Is a once-weekly injection or a daily tablet a better fit for my health and routine, and why?
2. Is any GLP-1 pill approved for my condition, and would my plan cover it?
3. Do any of my other medicines matter for a tablet? (Foundayo's label lists some that change how much orforglipron reaches the blood.³)
4. If my medicine ever changes, how would we manage the change, and what should I record in the first weeks?
5. What should I do if I miss a dose of the medicine I'm on?

More on getting ready: preparing for a GLP-1 doctor appointment.